Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Some mutations in cancer cells can be exploited for therapeutic intervention. However, for many cancer subtypes, including triple-negative breast cancer (TNBC), no frequently recurring aberrations could be identified to make such an approach clinically feasible. Characterized by a highly heterogeneous mutational landscape with few common features, many TNBCs cluster together based on their 'basal-like' transcriptional profiles. We therefore hypothesized that targeting TNBC cells on a systems level by exploiting the transcriptional cell state might be a viable strategy to find novel therapies for this highly aggressive disease. We performed a large-scale chemical genetic screen and identified a group of compounds related to the drug PKC412 (midostaurin). PKC412 induced apoptosis in a subset of TNBC cells enriched for the basal-like subtype and inhibited tumor growth in vivo. We employed a multi-omics approach and computational modeling to address the mechanism of action and identified spleen tyrosine kinase (SYK) as a novel and unexpected target in TNBC. Quantitative phosphoproteomics revealed that SYK inhibition abrogates signaling to STAT3, explaining the selectivity for basal-like breast cancer cells. This non-oncogene addiction suggests that chemical SYK inhibition may be beneficial for a specific subset of TNBC patients and demonstrates that targeting cell states could be a viable strategy to discover novel treatment strategies.

Original publication

DOI

10.15252/msb.20145664

Type

Journal article

Journal

Molecular systems biology

Publication Date

19/02/2015

Volume

11

Pages

789 - 789

Addresses

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Keywords

Cell Line, Tumor, Animals, Humans, Mice, Staurosporine, Transforming Growth Factor beta, Intracellular Signaling Peptides and Proteins, Antineoplastic Agents, Drug Delivery Systems, Xenograft Model Antitumor Assays, Gene Expression Profiling, Sequence Analysis, RNA, Proteomics, Signal Transduction, Apoptosis, Cell Differentiation, Cell Proliferation, Cell Survival, Female, STAT3 Transcription Factor, Protein-Tyrosine Kinases, Protein Interaction Domains and Motifs, Molecular Targeted Therapy, Molecular Docking Simulation, Triple Negative Breast Neoplasms, Syk Kinase